Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 91,621,400
  • Shares Outstanding, K 1,310,000
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.11
  • Price/Sales 2.99
  • Price/Cash Flow 4.99
  • Price/Book 4.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.38 +6.97%
on 02/09/17
73.30 -4.58%
on 02/07/17
-0.31 (-0.44%)
since 01/24/17
3-Month
65.38 +6.97%
on 02/09/17
76.98 -9.15%
on 01/04/17
-5.36 (-7.12%)
since 11/23/16
52-Week
65.38 +6.97%
on 02/09/17
103.10 -32.16%
on 04/26/16
-19.42 (-21.73%)
since 02/24/16

Most Recent Stories

More News
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.

ALIOF : 268.0600 (+0.38%)
GILD : 69.94 (+0.82%)
MDT : 81.03 (+0.36%)
UTHR : 146.71 (-0.50%)
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

CELG : 118.23 (-1.03%)
SRPT : 32.02 (+6.20%)
MDCO : 52.06 (+0.42%)
BMRN : 87.51 (-1.99%)
GILD : 69.94 (+0.82%)
AMGN : 174.56 (+0.32%)
ALXN : 131.54 (+0.84%)
Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

TSLA : 257.00 (+0.39%)
VXX : 18.09 (-1.04%)
GILD : 69.94 (+0.82%)
Five Major Myths about Options Trading

Five Major Myths about Options Trading

TSLA : 257.00 (+0.39%)
VXX : 18.09 (-1.04%)
GILD : 69.94 (+0.82%)
Five Major Myths about Options Trading

Five Major Myths about Options Trading

TSLA : 257.00 (+0.39%)
VXX : 18.09 (-1.04%)
GILD : 69.94 (+0.82%)
Gilead Receives Approval in Canada for ODEFSEY(TM) for the Treatment of HIV-1 Infection

- ODEFSEY is the Second Single Tablet Regimen Containing the DescovyTM Backbone and the Third Product in Gilead's New TAF Portfolio to Receive Approval in Canada -

GILD : 69.94 (+0.82%)
Robin L. Washington of Gilead Sciences, Inc. selected for Bay Area CFO of the Year Lifetime Achievement Award

12th annual CFO of the Year Awards recognizes area CFOs; proceeds from the event benefit Larkin Street Youth Services

GILD : 69.94 (+0.82%)
Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences

Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, has entered into an agreement with Gilead...

GILD : 69.94 (+0.82%)
Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

CYTK : 10.20 (+0.49%)
GILD : 69.94 (+0.82%)
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

AGIO : 47.82 (+0.89%)
RARE : 77.47 (+0.77%)
ZTS : 53.88 (+0.56%)
GILD : 69.94 (+0.82%)
REGN : 361.01 (+0.01%)
GSK : 41.56 (+0.17%)
SNY : 42.70 (+0.45%)
ALXN : 131.54 (+0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 70.71
1st Resistance Point 70.32
Last Price 69.94
1st Support Level 69.30
2nd Support Level 68.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.